Category: Acute Myocardial Infarction--Therapy Background: We investigated the predictor and prognostic factor for no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction (STEMI) treated with drug-eluting stent (DES).
Results:
No-reflow phenomenon after DES implantation occurred in 7.9 % of the patients. Patients with no-reflow were older, had higher Killip class, lower left ventricular ejection fraction, and more complex lesions, and needed longer intensive care. The levels of CK-MB, hs-CRP, and NT-proBNP were significantly higher in patients with no-reflow than those with normal reflow. Rates of in-hospital adverse events (IHAEs) and MACEs at 1 and 12 months were significantly higher in patients with no-reflow compared with those with normal reflow (IHAEs: 35.2% vs 15.5%, p<0.001; 1-month MACEs: 6.3% vs 2.6%, p=0.001; 12-month MACEs: 21.3% vs 15.3%, p=0.031). In multivariate analysis, no-reflow was an independent predictor of short-term (OR, 2.46, 95% CI 1.41-4.17, p<0.001) and long-term clinical outcomes (OR, 1.51, 95% CI 1.04-2.19, p=0.032). In addition, elevated NT-proBNP (OR, 2.46, 95% CI 1.41-4.17, p<0.001) and preprocedural TIMI grade 0/1 flow (OR, 2.15, 95% CI 1.22-3.79, p= 0.043) were independent predictors of no-reflow. In no-reflow group, additive use of cilostazol lowered 1-and 12-month MACEs (OR, 0.59, 95% CI 0.38-0.91, p=0.016; OR, 0.60, 95% CI 0.36-0.99, p=0.043).
Conclusions:
Angiographic no-reflow phenomenon after primary DES implantation for STEMI can be predicted by NT-proBNP levels. No-reflow was an independent predictor of increased mortality. NT-proBNP-guided approach may be useful in identifying patients at high risk of the no-reflow phenomenon after stenting and additive use of cilostazol was beneficial for short-and long-term outcomes in patients with no-reflow.
